Skip to main content

Table 1 Demographic and clinical characteristics for SZ patients and HC

From: Deficits of perceived spatial separation induced prepulse inhibition in patients with schizophrenia: relationships to symptoms and neurocognition

Variable HC SZ t/χ2 p
N = 50 N = 75
Gender (M/F) 38/12 54/21 0.25 0.68a
Smoke
 Ratio 68.0% 60.0% 0.83 0.45a
 Cigarettes per day 6.6 ± 8.8 7.3 ± 8.6 0.45 0.65b
Age (year) 42.9 ± 8.0 44.9 ± 6.7 1.57 0.12b
Education (year) 11.6 ± 3.2 10.8 ± 2.6 0.02 0.89b
Age of onset (year)   24.8 ± 6.7   
Recurrence times   4.7 ± 2.5   
Duration (year)   19.5 ± 8.4   
Medication
 FGA, n (%)   14 (18.7)   
 SGA, n (%)   40 (53.3)   
 FGA + SGA, n (%)   21 (18.0)   
 CPZ(mg/day)   300.6 ± 247.0   
PANSS score
 Total   62.3 ± 13.5   
 Positive   12.6 ± 4.7   
 Negative   19.7 ± 6.5   
 General   29.9 ± 5.7   
  1. Note: Data are expressed as mean ± SD, SD standard deviation, SZ schizophrenia patients, HC healthy controls, CPZ chlorpromazine equivalent dosage
  2. PANSS: positive and negative syndrome scale; a indicates p value for chi-square test; b indicates p value for independent sample t-test.